Frost replaces Moshe Many, who had been serving as interim chair and now will take the vice chair's seat. . With Hurvitz's resignation, Teva loses the man who spent 34 years building the company into a leading generics firm. But analysts said that Frost and Teva's other managers are well equipped to keep building. "The strength of Teva and one of its main assets is its broad and talented management structure," Bank Hapoalim analyst Gilad Sarig tells the Jerusalem Post. "The replacement of the chairman is not expected to have a significant impact on the company's activities." 
Share:  Frost replaces Moshe Many, who had been serving as interim chair and now will take the vice chair's seat. . With Hurvitz's resignation, <span class="company">Teva</span> loses the man who spent 34 years building the company into a leading generics firm.<span class="sent"> But analysts said that Frost and <span class="company">Teva</span>'s other managers are well equipped to keep building. "The strength of <span class="company">Teva</span> and one of its main assets is its broad and talented management structure," Bank Hapoalim analyst <span class="analyst">Gilad Sarig</span> tells the Jerusalem Post.</span> "The replacement of the chairman is not expected to have a significant impact on the company's activities." ..... With Hurvitz's resignation, <span class="company">Teva</span> loses the man who spent 34 years building the company into a leading generics firm.<span class="sent"> But analysts said that Frost and <span class="company">Teva</span>'s other managers are well equipped to keep building. "The strength of <span class="company">Teva</span> and one of its main assets is its broad and talented management structure," Bank Hapoalim analyst <span class="analyst">Gilad Sarig</span> tells the Jerusalem Post.</span> "The replacement of the chairman is not expected to have a significant impact on the company's activities." . Tweet this 

There's more movement in the Teva Pharmaceuticals executive suite. The world's biggest generics maker announced that chairman Eli Hurvitz, who had been on medical leave, is resigning his position to focus on his recovery. So Teva tapped vice chairman Dr. Phillip Frost to serve as chairman of the board. 
Share:  There's more movement in the <span class="company">Teva Pharma</span>ceuticals executive suite. The world's biggest generics maker announced that chairman Eli Hurvitz, who had been on medical leave, is resigning his position to focus on his recovery. So Teva tapped vice chairman Dr. Phillip Frost to serve as chairman of the board. Tweet this 

"The appointment of Frost as chairman of Teva is good news for shareholders, who will enjoy consecutive management in light of the long acquaintance built on many years between Frost, Hurvitz and Teva," said Gilad Sarig, chemicals and pharmaceuticals analyst at Bank Hapoalim. "The strength of Teva and one of its main assets is its broad and talented management structure. Therefore, the replacement of the chairman is not expected to have a significant impact on the company's activities.". Last month, Teva announced that Hurvitz, 78, was taking temporary leave from his duties for health reasons but was expected to return to his post. 
Share:  <span class="sent">"The appointment of Frost as chairman of <span class="company">Teva</span> is good news for shareholders, who will enjoy consecutive management in light of the long acquaintance built on many years between Frost, Hurvitz and <span class="company">Teva</span>," said <span class="analyst">Gilad Sarig</span>, chemicals and pharmaceuticals analyst at Bank Hapoalim.</span> "The strength of <span class="company">Teva</span> and one of its main assets is its broad and talented management structure. Therefore, the replacement of the chairman is not expected to have a significant impact on the company's activities.". Last month, <span class="company">Teva</span> announced that Hurvitz, 78, was taking temporary leave from his duties for health reasons but was expected to return to his post. Tweet this 

The auction is riveting drug makers and analysts because it pits the world's biggest maker of brand name drugs, the American company Pfizer , against the global leader in generics, Teva Pharmaceutical Industries , with headquarters in Israel. Pfizer is said to have bid as much as three billion euros — or about $4.1 billion — for Ratiopharm, Bloomberg reported last week, citing two people with knowledge of the talks. Besides Teva, analysts say, the other bidder is Actavis, a generic maker based in Iceland. 
Share:  The auction is riveting drug makers and analysts because it pits the world's biggest maker of brand name drugs, the American company Pfizer , against the global leader in generics, <span class="company">Teva</span> Pharmaceutical Industries , with headquarters in Israel. Pfizer is said to have bid as much as three billion euros — or about $4.1 billion — for Ratiopharm, Bloomberg reported last week, citing two people with knowledge of the talks. Besides <span class="company">Teva</span>, analysts say, the other bidder is Actavis, a generic maker based in Iceland. Tweet this 

But as the Wall Street Journal points out, both Teva Pharmaceutical Industries and Merck are likely to cheer an appeals court decision on the blood pressure drugs Cozaar and Hyzaar. . The new ruling awards 180 day exclusivity to Teva on its versions of both drugs, reversing a lower court's decision to deny that first to market advantage. Clearly, that's a win for Teva; it will have six months as the only copycat provider of two of the most popular hypertension meds on the market. 
Share:  But as the Wall Street Journal points out, both <span class="company">Teva</span> Pharmaceutical Industries and Merck are likely to cheer an appeals court decision on the blood pressure drugs Cozaar and Hyzaar. . The new ruling awards 180 day exclusivity to <span class="company">Teva</span> on its versions of both drugs, reversing a lower court's decision to deny that first to market advantage. Clearly, that's a win for <span class="company">Teva</span>; it will have six months as the only copycat provider of two of the most popular hypertension meds on the market. Tweet this 

, whose solutions facilitate data transmission among servers, communications infrastructure and storage, off 1.1%. Looking at the Bank of America Merrill Lynch report, when Israel is reclassified as a developed market for investing index purposes at the end of May, analysts Haim Israel and Micha Goldberg calculate the net passive money inflow to Israel at $3.3 billion, with $2.1 billion going to shares of Teva Pharmaceutical. 
Share:  , whose solutions facilitate data transmission among servers, communications infrastructure and storage, off 1.1%.<span class="sent"> Looking at the Bank of America Merrill Lynch report, when Israel is reclassified as a developed market for investing index purposes at the end of May, analysts <span class="analyst">Haim Israel</span> and Micha Goldberg calculate the net passive money inflow to Israel at $3.3 billion, with $2.1 billion going to shares of <span class="company">Teva Pharma</span>ceutical.</span>..., whose solutions facilitate data transmission among servers, communications infrastructure and storage, off 1.1%.<span class="sent"> Looking at the Bank of America Merrill Lynch report, when Israel is reclassified as a developed market for investing index purposes at the end of May, analysts <span class="analyst">Haim Israel</span> and Micha Goldberg calculate the net passive money inflow to Israel at $3.3 billion, with $2.1 billion going to shares of <span class="company">Teva Pharma</span>ceutical.</span> Tweet this 

, whose solutions facilitate data transmission among servers, communications infrastructure and storage, off 1.1%. Looking at the Bank of America Merrill Lynch report, when Israel is reclassified as a developed market for investing index purposes at the end of May, analysts Haim Israel and Micha Goldberg calculate the net passive money inflow to Israel at $3.3 billion, with $2.1 billion going to shares of Teva Pharmaceutical. 
Share:  , whose solutions facilitate data transmission among servers, communications infrastructure and storage, off 1.1%.<span class="sent"> Looking at the Bank of America Merrill Lynch report, when Israel is reclassified as a developed market for investing index purposes at the end of May, analysts <span class="analyst">Haim Israel</span> and Micha Goldberg calculate the net passive money inflow to Israel at $3.3 billion, with $2.1 billion going to shares of <span class="company">Teva Pharma</span>ceutical.</span>..., whose solutions facilitate data transmission among servers, communications infrastructure and storage, off 1.1%.<span class="sent"> Looking at the Bank of America Merrill Lynch report, when Israel is reclassified as a developed market for investing index purposes at the end of May, analysts <span class="analyst">Haim Israel</span> and Micha Goldberg calculate the net passive money inflow to Israel at $3.3 billion, with $2.1 billion going to shares of <span class="company">Teva Pharma</span>ceutical.</span> Tweet this 

Several weeks ago, the company its 2010 outlook and predicted earnings per share of $4.40 to $4.60 and revenues of $16 billion for the year. "Heading into what we believe will be an exceptionally strong 2010, we remain encouraged by Teva's overall sales trends," JPMorgan analyst Chris Schott in clients' note. As Big Pharma companies show flat earnings, Teva's growth shines. 
Share:  Several weeks ago, the company its 2010 outlook and predicted earnings per share of $4.40 to $4.60 and revenues of $16 billion for the year.<span class="sent"> "Heading into what we believe will be an exceptionally strong 2010, we remain encouraged by <span class="company">Teva</span>'s overall sales trends," JPMorgan analyst <span class="analyst">Chris Schott</span> in clients' note.</span> As Big Pharma companies show flat earnings, <span class="company">Teva</span>'s growth shines. Tweet this 

The most active issue was Teva, trading up 14% Teva /quotes/comstock/15*!teva /quotes/nls/teva ( TEVA 5874 , +174 , +305% ) was reiterated overweight at Barclays Capital, where analysts Richard B Silver and Ann Trimble raised their price target to $69 from $66 
Share:  <span class="sent">The most active issue was <span class="company">Teva</span>, trading up 14% <span class="company">Teva</span> /quotes/comstock/15*!teva /quotes/nls/teva ( TEVA 5874 , +174 , +305% ) was reiterated overweight at Barclays Capital, where analysts Richard B Silver and Ann Trimble raised their price target to $69 from $66</span> Tweet this 

He raised his 12 month price target to $30 from $27 Teva Pharmaceutical Industries Ltd: Deutsche Bank analyst David Steinberg reiterated his buy rating on shares of Teva Pharmaceutical Industries Ltd on Feb 16 Teva, the world's largest maker of generic drugs, said on Feb 16 that fourth quarter profit rose 28% on revenue from its top selling product, the Copaxone multiple sclerosis treatment 
Share:  He raised his 12 month price target to $30 from $27<span class="sent"> <span class="company">Teva</span> Pharmaceutical Industries Ltd: Deutsche Bank analyst <span class="analyst">David Steinberg</span> reiterated his buy rating on shares of <span class="company">Teva</span> Pharmaceutical Industries Ltd on Feb 16</span> <span class="company">Teva</span>, the world's largest maker of generic drugs, said on Feb 16 that fourth quarter profit rose 28% on revenue from its top selling product, the Copaxone multiple sclerosis treatment...He raised his 12 month price target to $30 from $27<span class="sent"> <span class="company">Teva</span> Pharmaceutical Industries Ltd: Deutsche Bank analyst <span class="analyst">David Steinberg</span> reiterated his buy rating on shares of <span class="company">Teva</span> Pharmaceutical Industries Ltd on Feb 16</span> <span class="company">Teva</span>, the world's largest maker of generic drugs, said on Feb 16 that fourth quarter profit rose 28% on revenue from its top selling product, the Copaxone multiple sclerosis treatment Tweet this